Int J Mol Sci. 2025 Sep 18;26(18):9083. doi: 10.3390/ijms26189083.
ABSTRACT
Pancreatic cancer remains a lethal disease despite advances in surgery and systemic treatment in the last two decades, underscoring the urgent need to better understand its biological underpinnings. Despite remarkable advances in the molecular characterization of pancreatic ductal adenocarcinoma (PDAC), clinically actionable biomarkers remain scarce, and current treatment remains empiric. Transcriptomic subtypes such as "classical" and "basal-like" offer some prognostic value, but their ability to guide real-time treatment decisions is limited. In this review, we explore the limitations of current biomarker strategies, in particular subtype-based classifications, and argue for a functional reframing of biomarker development in PDAC, centered on patient-derived organoids (PDOs). We explore four key domains in which PDOs deepen our understanding of therapeutic response and resistance, namely, drug response phenotyping, modeling chemoresistance, incorporating tumor microenvironmental complexity through co-culture systems, and more functional profiling through proteomic and metabolomic approaches. Together, these applications move PDOs beyond static avatars of the tumor to dynamic platforms capable of capturing clinically relevant biology. As functional precision medicine gains traction, PDOs may offer a path to more tailored, responsive treatment strategies in a cancer where new options are urgently needed.
PMID:41009646 | PMC:PMC12470908 | DOI:10.3390/ijms26189083